Form 4: Regulus Therapeutics Director, Pascale Witz, Acquires 30,000 Stock Options

Director Pascale Witz acquired 30,000 stock options in Regulus Therapeutics Inc. on May 16, 2024, according to a Form 4 filing.

Summary

• Pascale Witz, a director of Regulus Therapeutics Inc., acquired 30,000 stock options on May 16, 2024.
• The options have an exercise price of $2.01.
• These options were granted automatically under the company's Non-Employee Director's Compensation policy.
• The options will vest ratably over twelve months, becoming fully vested one year after the grant date or at the next annual stockholder meeting, contingent upon continuous service.
• Following the transaction, Pascale Witz directly owns 30,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard compensation practice. The grant of options is generally viewed positively as it aligns director interests with shareholders, but it's a routine event.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

This filing is a routine disclosure related to director compensation, which is a common practice in publicly traded companies to align management and shareholder interests.

Stakeholder Impact

• Shareholders may view the option grant positively as it aligns the director's interests with the company's performance.
• The director is incentivized to contribute to the company's success to increase the value of the options.

Key Dates